Illi Ari, Setälä-Soikkeli Eija, Viikki Merja, Poutanen Outi, Huhtala Heini, Mononen Nina, Lehtimäki Terho, Leinonen Esa, Kampman Olli
University of Tampere, Medical School, Tampere, Finland.
Neuroreport. 2009 Aug 5;20(12):1125-8. doi: 10.1097/WNR.0b013e32832eb708.
Genes that regulate the serotonin signalling system are potential targets for research in the aetiology of mood disorders and also in the treatment response of serotonin reuptake inhibitors. In this study, we evaluated the association of seven serotonin signal transduction-linked single nucleotide polymorphisms [HTR1A (rs6295), HTR2A (rs6313, rs6311 and rs7997012), HTR6 (rs1805054), TPH1 (rs1800532) and TPH2 (rs1386494)] with major depressive disorder and/or treatment outcome with serotonin reuptake inhibitors. Patients who met the criteria for major depressive disorder were treated for 6 weeks with fluoxetine, paroxetine or citalopram. The treatment response was evaluated with the Montgomery-Asberg Depression Rating Scale, and according to predefined response criteria, the patients were divided into responders, nonresponders, remitters and nonremitters. Altogether, 86 patients completed the entire study according to the study protocol. We had also a control population (N = 395) of healthy blood donors. None of the seven single nucleotide polymorphisms was associated with major depressive disorder or with treatment response in our study population of Finnish individuals.
调节血清素信号系统的基因是研究情绪障碍病因以及血清素再摄取抑制剂治疗反应的潜在靶点。在本研究中，我们评估了七个与血清素信号转导相关的单核苷酸多态性[5-羟色胺受体1A（HTR1A，rs6295）、5-羟色胺受体2A（HTR2A，rs6313、rs6311和rs7997012）、5-羟色胺受体6（HTR6，rs1805054）、色氨酸羟化酶1（TPH1，rs1800532）和色氨酸羟化酶2（TPH2，rs1386494）]与重度抑郁症和/或血清素再摄取抑制剂治疗结果的关联。符合重度抑郁症标准的患者用氟西汀、帕罗西汀或西酞普兰治疗6周。用蒙哥马利-阿斯伯格抑郁评定量表评估治疗反应，并根据预先定义的反应标准，将患者分为反应者、无反应者、缓解者和未缓解者。根据研究方案，共有86名患者完成了整个研究。我们还有一个由健康献血者组成的对照人群（N = 395）。在我们的芬兰个体研究人群中，这七个单核苷酸多态性均与重度抑郁症或治疗反应无关。
